LONDON (MarketWatch) -- Shares in Shire Pharmaceuticals rose 1.3% in London on Friday ahead a decision by the U.S. Food & Drug Administration on whether to approve Shire and New River Pharmaceuticals follow on product to Adderall XR. “Given the significance to Shire of Adderall XR - which accounted for around 55% of its 2005 sales -this news is likely to be highly significant,” said analysts at Charles Stanley Securities. They said that they continue to believe the product, NRP-104, will get approval to launch early next year.
